Pharvaris' stock jumps on pivotal success in rare genetic disease
Pharvaris claims it achieved “injectable-like efficacy” in a once-daily pill for a debilitating genetic disease. The experimental drug, an extended-release version of deucrictibant, is designed to prevent swelling attacks in patients with a rare disease ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
